SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Cadus Corp – ‘S-8 POS’ on 12/23/97

As of:  Tuesday, 12/23/97   ·   Effective:  12/23/97   ·   Accession #:  889812-97-2729   ·   File #:  333-21871

Previous ‘S-8 POS’:  ‘S-8 POS’ on 3/10/97   ·   Next:  ‘S-8 POS’ on 4/5/16   ·   Latest:  ‘S-8 POS’ on 4/5/16

  in   Show  &   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

12/23/97  Cadus Corp                        S-8 POS    12/23/97    4:12K                                    Global Fin'l Press/NY/FA

Post-Effective Amendment to an S-8   —   Form S-8
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-8 POS     Post-Effective Amendment No. 2                         5     21K 
 2: EX-4        Amendment No. 2 to Cadus Pharmaceutical                1      5K 
                          Corporation 1996 Incentive Plan                        
 3: EX-5        Opinion of Morrison Cohen Singer & Weinstein, LLP,     2±     8K 
                          as to the Validity of the Securities                   
                          Being Registered                                       
 4: EX-23.1     Consent of Kpmg Peat Marwick LLP                       1      5K 


S-8 POS   —   Post-Effective Amendment No. 2

S-8 POS1st Page of 5TOCTopPreviousNextBottomJust 1st
 

Registration No. 333-21871 ================================================================================ SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ------------------- POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CADUS PHARMACEUTICAL CORPORATION ------------------------------------------------------ (Exact name of registrant as specified in its charter) Delaware -------------------------------------------------------------- (State or other jurisdiction of incorporation or organization) 13-3660391 ------------------------------------ (I.R.S. Employer Identification No.) 777 Old Saw Mill River Road, Tarrytown, New York 10591-6705 ----------------------------------------------------------- (Address of Principal Executive Offices) Cadus Pharmaceutical Corporation 1993 Stock Option Plan Cadus Pharmaceutical Corporation 1996 Incentive Plan Written Compensation Contracts with Certain Employees Written Compensation Contracts with Non-Employee Directors Written Compensation Contracts with Certain Consultants ----------------------------------------------------------- (Full Title of the Plan) Jeremy M. Levin Cadus Pharmaceutical Corporation 777 Old Saw Mill River Road Tarrytown, New York 10591-6705 --------------------------------------- (Name and Address of Agent For Service) (914) 345-3344 ------------------------------------------------------------- (Telephone Number, Including Area Code, of Agent For Service) Copy to: Salomon R. Sassoon, Esq. Morrison Cohen Singer & Weinstein, LLP 750 Lexington Avenue New York, New York 10022 (212) 735-8600 ================================================================================
S-8 POS2nd Page of 5TOC1stPreviousNextBottomJust 2nd
Cadus Pharmaceutical Corporation (the "Company") hereby amends the Registration Statement on Form S-8 (the "Registration Statement") filed with the Securities and Exchange Commission (the "SEC") on February 14, 1997, File No. 333-21871, as amended by Post-Effective Amendment No. 1 thereto, filed with the SEC on March 10, 1997, in order to register an additional 1,000,000 shares of Common Stock that are issuable upon the exercise of options and stock appreciation rights which may be granted under the Company's 1996 Incentive Plan (the "Plan"), which additional 1,000,000 shares of Common Stock were added pursuant to Amendment No. 2 to the Plan adopted by the Board of Directors of the Company on December 11, 1997. The contents of the Registration Statement filed with the SEC by the Company on February 14, 1997, Post-Effective Amendment No. 1 to the Registration Statement filed with the SEC on March 10, 1997, and all documents referenced therein are incorporated herein by reference.
S-8 POS3rd Page of 5TOC1stPreviousNextBottomJust 3rd
CALCULATION OF REGISTRATION FEE [Enlarge/Download Table] ================================================================================================================================== Title of Securities Amount to be Proposed Maximum Proposed Maximum Amount of to be Registered Registered Offering Price Per Share Aggregate Offering Price Registration Fee ================================================================================================================================== Common Stock, par value $0.01 per share, issuable upon exercise of options and stock appreciation rights which may be granted Additional under 1996 Incentive Plan 1,000,000 $8.3125(1) $8,312,500.00 $2,452.19 ================================================================================================================================== Total Registration Fee . . . . . . . . . . . . . . . . . . . . . . . . . . $2,452.19 ================================================================================================================================== ------------------------- (1) Estimated in accordance with Rules 457(c) and (h) solely for the purpose of calculating the registration fee and based upon the average of the high and low trade prices of Common Stock of Cadus Pharmaceutical Corporation as reported by the NASDAQ Stock Market on December 18, 1997. 1
S-8 POS4th Page of 5TOC1stPreviousNextBottomJust 4th
SIGNATURES Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 2 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Tarrytown, State of New York, on this 17th day of December, 1997. CADUS PHARMACEUTICAL CORPORATION By: /s/ Jeremy M. Levin ------------------------------------- Jeremy M. Levin President and Chief Executive Officer Pursuant to the requirements of the Securities Act of 1933, as amended, this Post-Effective Amendment No. 2 to the Registration Statement has been signed below by the following persons in the capacities and on the dates indicated: [Enlarge/Download Table] Signature Title Date --------- ----- ---- /s/ Jeremy M. Levin President and Chief Executive Officer December 17, 1997 ------------------------------------ (Principal Executive Officer) and Jeremy M. Levin Chairman of the Board of Directors /s/ James S. Rielly Director of Finance, Controller, December 17, 1997 ------------------------------------ Treasurer and Secretary (Principal James S. Rielly Financial and Accounting Officer) Director December 17, 1997 ------------------------------------ Carl C. Icahn Director December 17, 1997 ------------------------------------ Theodore Altman /s/ Harold First Director December 17, 1997 ------------------------------------ Harold First * Director December 17, 1997 ------------------------------------ Peter Liebert * Director December 17, 1997 ------------------------------------ Robert Mitchell * Director December 17, 1997 ------------------------------------ Lawrence Muschek Director December 17, 1997 ------------------------------------ Mark H. Rachesky Director December 17, 1997 ------------------------------------ Leon E. Rosenberg * Director December 17, 1997 ------------------------------------ Nicole Vitullo Director December 17, 1997 ------------------------------------ Samuel D. Waksal * Director December 17, 1997 ------------------------------------ Jack G. Wasserman *By: /s/ Jeremy M. Levin ------------------------------- Jeremy M. Levin, Attorney-in-Fact 2
S-8 POSLast Page of 5TOC1stPreviousNextBottomJust 5th
EXHIBIT INDEX No. Description --- ----------- 4. Amendment No. 2 to Cadus Pharmaceutical Corporation 1996 Incentive Plan. 5. Opinion of Morrison Cohen Singer & Weinstein, LLP, as to the validity of the securities being registered. 23.1 Consent of KPMG Peat Marwick LLP. 23.2 Consent of Morrison Cohen Singer & Weinstein, LLP (contained in its Opinion filed as Exhibit 5).

Dates Referenced Herein   and   Documents Incorporated by Reference

Referenced-On Page
This ‘S-8 POS’ Filing    Date First  Last      Other Filings
Filed on / Effective on:12/23/97
12/18/973
12/17/974
12/11/972
3/10/972S-8 POS,  SC 13G
2/14/972S-8
 List all Filings 
Top
Filing Submission 0000889812-97-002729   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2018 Fran Finnegan & Company.  All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., Nov. 17, 10:40:59.0am ET